TRANSFORMING
POWERFUL
PROINFLAMMATORY
BIOLOGY
INTO NOVEL THERAPIES FOR CANCER PATIENTS
Our VISION
To make nanopolymer drug delivery a proven, safe, and effective solution accessible worldwide, while enjoying the journey of developing life-saving innovations.
Our MISSION
Save patients’ lives with nanotechnology
Pioneering the Interleukin-12 prodrug Axis
Broad applicability of Red Arrow prodrug technology including:
Small peptide to antibody full chain
Cationic protein to anionic protein
Lead asset – RA001 – IND planned for 2027
Based on novel technologies developed by a pioneer of nanomedicine, Prof. Dr. Horacio Cabral from the University of Tokyo
Main Investors: The University of Tokyo Edge Capital (UTEC), Beyond Next Ventures (BNV)
Our Science
News
| 2024-09 |
Red Arrow is now a proud recipient of $2.4M USD in non-dilutive funding from Japan's NEDO (New Energy and Industrial Technology Development Organization) STS (Seed-stage Technology-based Startups) Grant. |
| 2024-04 |
We are proud to announce our $4.5M raise from University of Tokyo Edge Capital, Beyond Next Ventures, Keio Innovation Initiative, and Osaka University Venture Capital. Red Arrow Therapeutics Inc. closes $4.5M Seed Extension round |
| 2024-03 |
Red Arrow Therapeutics Inc. and ASKA Pharmaceutical Co., Ltd. Announce Collaboration on Novel Preeclampsia Treatment Red Arrow Therapeuticsとあすか製薬、妊娠高血圧症候群の新規治療薬開発のための共同研究契約を締結 |
| 2024-03 |
Red Arrow Therapeutics has been featured in Nikkei, Japan's prestigious business newspaper. We're immensely grateful for the recognition from Nikkei and the opportunity to showcase our pioneering work on an international platform. This acknowledgment comes at an exciting time as we continue to advance toward our goal of revolutionizing biopharmaceutical delivery. |
| 2023-07 | Red Arrow Therapeutics, Co., Ltd. has been recognized as one of the 'Top 10 Most Promising Biotech Startups from Asia - 2023' by Asia Business Outlook magazine in their July issue! This prestigious recognition validates our commitment to innovation and transformative solutions in cancer immunotherapy. Join us in celebrating this milestone achievement! https://www.asiabusinessoutlook.com/asia-startups/vendor/red-arrow-therapeutics-a-beacon-of-hope-for-cancer-patients-cid-1369.html |
| 2023-06 | Rika Tajima, Business Manager of Red Arrow Therapeutics, Co., Ltd. participated in the highly acclaimed Pitch Perfect Startup. It was an incredible experience to showcase Red Arrow Therapeutics' vision and progress to a distinguished panel of fellow founders and investors. The event was an exceptional platform for fostering connections and exchanging groundbreaking ideas. She had the privilege of engaging with some of the brightest minds in the startup ecosystem, discussing industry trends, and exploring potential collaborations. |
| 2023-06 | Red Arrow Therapeutics, Co., Ltd. has been featured in a recent article published in Nikkei Biotechnology and Business. We are honored to be recognized and grateful for the opportunity to showcase Red Arrow's innovation in the biotechnology industry. https://bio.nikkeibp.co.jp/atcl/column/16/021500017/060700282/ |
| 2023-06 | Red Arrow Therapeutics, Co., Ltd. has been accepted into the prestigious program U.S. Early Stage Growth Cohort by MassChallenge. We are honored to be among the selected few who will receive guidance, mentorship, and resources to accelerate our growth and take our business to new heights. This opportunity will empower us to unlock our full potential and significantly impact our industry. |
| 2023-05 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. presented at a Plug and Play University Pitch Sessions organized in Japan. This session featured UTokyo, Osaka, Kyoto, NTU, NUS, and Peking University alumni. |
| 2023-04 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. presented our cutting-edge drug discovery technology at Demo Day Berkeley SKYDECK. His pitch was engaging and informative, as he explained the unique approach that Red Arrow Therapeutics, Co., Ltd. is taking to drug development. During his pitch, Miyazaki shared some exciting early results from the company's research, highlighting the potential impact of their technology on the medical field. He also discussed the challenges facing the biotech industry and how Red Arrow Therapeutics is uniquely positioned to address them. |
| 2023-04 | Prof. Horacio Cabral from Red Arrow Therapeutics, Co., Ltd. presented our groundbreaking research at the Late-Breaking Research session on Immunology 3. The abstract, titled "pH-sensitive polymeric micelles loading IL-12 profoundly inflame the tumor microenvironment to eradicate cold tumors", promises to be a game-changer in the field of cancer research. The research focuses on using pH-sensitive polymeric micelles to deliver IL-12 to the tumor microenvironment, resulting in the eradication of cold tumors. This breakthrough could have a significant impact on cancer treatment and could potentially lead to new treatment options for patients. Congratulations to Dr. Cabral Lorenzo Horac on this incredible achievement. |
| 2023-04 | Prof. Horacio Cabral from Red Arrow Therapeutics, Co., Ltd. presented "pH-sensitive polymeric micelles loading IL-12 profoundly inflame the tumor microenvironment to eradicate cold tumors" at 2023 American Association for Cancer Research (AACR) conference. The research on using pH-sensitive polymeric micelles to deliver IL-12 to the tumor microenvironment has the potential to make a significant impact in the field of cancer immunotherapy. Congratulations to Dr. Horacio Cabral and their team for this incredible achievement! |
| 2023-02 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. has won the X-HUB Tokyo Global Startup Accelerator London Demo Day! He had the privilege to showcase our innovative solution to a panel of top industry leaders and investors, and came out on top among a pool of talented startups. We're grateful for the opportunity to share our vision and receive invaluable feedback from the judges. This win is a testament to the hard work and determination of our team, and we're eager to use this as a springboard to take our company to new heights. Thank you to everyone who has supported us along the way, and here's to continuing to push the boundaries of what's possible. |
| 2023-02 | "Exciting news in the world of healthcare!” A recent study led by Prof. Horacio Cabral (Visiting Scientist of iCONM / Associate Professor of Bioengineering, Graduate School of Engineering, University of Tokyo) and in collaboration with a group led by Prof. Kazuhiro Kakimi (Project Professor, Graduate School of Medicine, University of Tokyo) and iCONM has shown that pH-activated nanocytokines based on IL-12 can safely and effectively treat diseases such as cancer and autoimmune disorders. This is a promising step forward in the development of targeted and efficient therapies. https://phys.org/news/2023-02-ph-activated-nanocytokines-based-il-safely.html https://www.miragenews.com/ph-activated-nanocytokines-based-on-il-12-942682/ |
| 2023-02 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. gave a presentation on the hybrid event "UTEC UTokyo Meetup" organized by The University of Tokyo (UTokyo) where he discussed the reasons that motivated him to start his businesses, the challenges he has faced, the key milestones he has reached so far, and his future prospects. https://www.ut-ec.co.jp/english/news/utec_news/utec-utokyo-meetup |
| 2023-02 | Red Arrow Therapeutics, Co. Ltd. has been selected as one of the top 100 companies in the Entrepreneurship World Cup (EWC) global finals! We're proud to be part of this group of innovative and dynamic companies that are advancing the field of entrepreneurship. The EWC is a global competition that supports and celebrates entrepreneurs from all over the world. It provides resources, training, and a platform for entrepreneurs to pitch their ideas and showcase their innovations. Being selected as one of the top 100 companies is a great honor, and we're grateful for this opportunity to showcase our work on a global stage.We want to thank the EWC organizers for this recognition, and our team for their hard work and dedication. We also want to congratulate the other top 100 companies and wish everyone the best of luck in the global finals. To learn more about the EWC and the top 100 companies, visit the link below: https://www.genglobal.org/ewc/100-and-coming-companies-advance-entrepreneurship-world-cup-global-finals |
| 2022-12 | Dr.Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. participated in the online event series focused on the Silicon Valley Mindset, “ 7 Steps from Innovation to Funding” organized by Pitch Global. This event was an excellent opportunity to learn more about new strategies for business growth, competency, and productivity. |
| 2022-12 | Red Arrow Therapeutics, Co. Ltd. attended “Japan Innovation Night” which featured pitches from 14 Japanese startups in biotech and healthtech, as well as Japanese foods and beverages. Furthermore, this event featured a panel which was mainly focused on breaking down barriers for women in innovation. Red Arrow Therapeutics is highly focused on promoting the creation of a supportive work environment for women and increase the number of female members. |
| 2022-11 | Our senior researcher West Paraiso, PhD, received an award as Distinguished International Alumnus from the University of the Philippines. Congratulations, West! |
| 2022-11 | Red Arrow Therapeutics, Co. Ltd. has been selected to join UC Berkeley's Berkeley SkyDeck Accelerator Cohort Program which has a 1.5% acceptance rate worldwide. In the program, we are able to access global top advisors, mentors, and investors to help us to grow our innovative ideas and businesses. We appreciate the support of the whole team and its dedication to growing Red Arrow in the state. https://skydeck.berkeley.edu/ |
| 2022-10 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. delivered a pitch presentation to the featured investors at Pitch to Lifesciences VC's/CVC's/Angels+ Investor during meeting at University of California, Berkeley. |
| 2022-09 | Red Arrow Therapeutics, Co. Ltd. has been selected to join 2022 CIC-JETRO Startup City (Bio/Healthcare), an acceleration program for startups looking to expand globally. We learned valuable knowledge from top accelerators and meeting with overseas investors and colleagues in this program. https://www.jetro.go.jp/services/gsap.html |
| 2022-08 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. gave a pitch presentation in front of SrSF Investors @UC Berkeley at the PITCH GLOBAL event (via zoom). |
| 2022-08 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. gave a pitch to CVC's/VC's' angels+TDK&SK Group Thought Leadership that organized by the PITCH GLOBAL. |
| 2022-07 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. attended the Venture Summit West from July 19-20, 2022, in Silicon Valley, CA. |
| 2022-04 | Prof. Horacio Cabral from Red Arrow Therapeutics, Co., Ltd. presented promising preclinical data of RA-001 (pH-sensitive polymeric micelles loading IL-12) at AACR Annual Meeting 2022. RA-001 demonstrated a potent anti-tumor immunity in multiple tumor models. Furthermore, RA-001 showed high efficiacy as monotherapy and in combination with immune checkpoint inhibitors. |
| 2022-03 | Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. joint a pitch event, namely, STEP to Biotech/Healthcare Startups powered by CIC/LINK-J. He performed two presentations to spread a company overview and to look for talented persons. |